Cargando…

Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2 - implications for a combinatorial treatment

Despite the introduction of new treatment options for multiple myeloma (MM), a majority of patients relapse due to the development of resistance. Unraveling new mechanisms underlying resistance could lead to identification of possible targets for combinatorial treatment. Using TRAF3 deleted/mutated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duvefelt, Charlotte Fristedt, Lub, Susanne, Agarwal, Prasoon, Arngården, Linda, Hammarberg, Anna, Maes, Ken, Van Valckenborgh, Els, Vanderkerken, Karin, Wiklund, Helena Jernberg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653030/ https://www.ncbi.nlm.nih.gov/pubmed/26036313

Ejemplares similares

Novel strategies to target the ubiquitin proteasome system in multiple myeloma
por: Lub, Susanne, et al.
Publicado: (2015)

Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2
por: Darding, M, et al.
Publicado: (2011)

The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic
por: Bieghs, Liesbeth, et al.
Publicado: (2014)

Polycomb Target Genes Are Silenced in Multiple Myeloma
por: Kalushkova, Antonia, et al.
Publicado: (2010)

LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC
por: Yang, Chengcheng, et al.
Publicado: (2016)

Cytoplasmic and Nuclear Functions of cIAP1
por: Zadoroznyj, Aymeric, et al.
Publicado: (2022)

Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation
por: Gill, Catherine, et al.
Publicado: (2009)

Inhibitor of apoptosis proteins, NAIP, cIAP1 and cIAP2 expression during macrophage differentiation and M1/M2 polarization
por: Morón-Calvente, Virginia, et al.
Publicado: (2018)

Expression and Correlation of Cell-Free cIAP-1 and cIAP-2 mRNA in Breast Cancer Patients: A Study from India
por: Verma, Amit Kumar, et al.
Publicado: (2020)

Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma
por: Maes, Ken, et al.
Publicado: (2013)

Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells
por: Lub, Susanne, et al.
Publicado: (2015)

E2F1 binds to the peptide-binding groove within the BIR3 domain of cIAP1 and requires cIAP1 for chromatin binding
por: Allègre, Jennifer, et al.
Publicado: (2018)

Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency
por: Cheng, Le, et al.
Publicado: (2010)

Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma
por: Wang, Jinheng, et al.
Publicado: (2016)

cIAP-1 Controls Innate Immunity to C. pneumoniae Pulmonary Infection
por: Prakash, Hridayesh, et al.
Publicado: (2009)

Activation of noncanonical NF-κB requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2, TRAF3 and the kinase NIK
por: Zarnegar, Brian J., et al.
Publicado: (2008)

Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models
por: Hu, Jinsong, et al.
Publicado: (2012)

Bivalent IAP antagonists inhibit TRAF2-bound cIAPs and limit TNF-mediated NF-κB signaling
por: Condon, Stephen M
Publicado: (2016)

cIAP1 promotes proliferation and migration and prevents apoptosis in gallbladder cancer in vitro
por: Su, Wei, et al.
Publicado: (2019)

TRIM56 promotes malignant progression of glioblastoma by stabilizing cIAP1 protein
por: Yang, Xu, et al.
Publicado: (2022)

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
por: Bieghs, Liesbeth, et al.
Publicado: (2010)

The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells
por: Wang, Jinheng, et al.
Publicado: (2015)

Bivalent IAP antagonists, but not monovalent IAP antagonists, inhibit TNF-mediated NF-κB signaling by degrading TRAF2-associated cIAP1 in cancer cells
por: Mitsuuchi, Y, et al.
Publicado: (2017)

TAK1 kinase determines TRAIL sensitivity by modulating reactive oxygen species and cIAP
por: Morioka, Sho, et al.
Publicado: (2009)

HAX1 regulates E3 ubiquitin ligase activity of cIAPs by promoting their dimerization
por: Choi, Jin Sun, et al.
Publicado: (2014)

PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1
por: Guo, Haihong, et al.
Publicado: (2019)

Correction: cIAP1 promotes proliferation and migration and prevents apoptosis in gallbladder cancer in vitro
Publicado: (2019)

USP11: A key regulator of cIAP2 stability and sensitivity to SMAC mimetics
por: Lee, Eun-Woo, et al.
Publicado: (2015)

cIAP1/2 are involved in the radiosensitizing effect of birinapant on NSCLC cell line in vitro
por: Sun, Hao, et al.
Publicado: (2021)

The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma
por: Maes, Ken, et al.
Publicado: (2014)

Ceramide targets xIAP and cIAP1 to sensitize metastatic colon and breast cancer cells to apoptosis induction to suppress tumor progression
por: Paschall, Amy V, et al.
Publicado: (2014)

Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells
por: De Veirman, Kim, et al.
Publicado: (2015)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential
por: Bieghs, Liesbeth, et al.
Publicado: (2016)

cIAP1 regulates the EGFR/Snai2 axis in triple-negative breast cancer cells
por: Majorini, Maria Teresa, et al.
Publicado: (2018)

cIAP2 promotes gallbladder cancer invasion and lymphangiogenesis by activating the NF‐κB pathway
por: Jiang, Xiaojie, et al.
Publicado: (2017)

RETRACTED ARTICLE: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
por: La, V., et al.
Publicado: (2017)

TWEAK Promotes the Proliferation of Squamous Cell Carcinoma Cells Through Activating cIAP1 Signals
por: Liang, Lili, et al.
Publicado: (2020)

Retraction Note: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
por: La, V., et al.
Publicado: (2021)

Cellular inhibitor of apoptosis 2 (cIAP2) restricts neuroinflammation during experimental autoimmune encephalomyelitis
por: Biswas, Debolina D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4muad46eqco4oku8l566hdg50o